Title:
BIFUNCTIONAL MOLECULE BINDING TO HUMAN TGFβ AND PD-L1, AND USE THEREOF
Document Type and Number:
WIPO Patent Application WO/2022/188865
Kind Code:
A1
Abstract:
Provided are a bifunctional molecule capable of binding to human transforming growth factor β (TGFβ) and human programmed death ligand 1 (PD-L1), a pharmaceutical composition thereof, and a use thereof in the treatment of cancer. The bifunctional molecule has high affinity for PD-L1, can significantly promote the secretion of IL-2 and IFN-γ, enhances T cell immune responses, can block TGFβ with high specificity, and thus can be used for the treatment of cancer. Also provided is a monoclonal antibody that binds to human PD-L1 or an antigen-binding fragment thereof.
Inventors:
WANG ZHONG (CN)
ZHANG HAIZHOU (CN)
ZHU ZIYAN (CN)
LI YUJUAN (CN)
ZHANG MENG (CN)
BAI SHENGDAN (CN)
ZHANG HAIZHOU (CN)
ZHU ZIYAN (CN)
LI YUJUAN (CN)
ZHANG MENG (CN)
BAI SHENGDAN (CN)
Application Number:
PCT/CN2022/080364
Publication Date:
September 15, 2022
Filing Date:
March 11, 2022
Export Citation:
Assignee:
BJ BIOSCIENCE INC (CN)
International Classes:
A61K38/17; A61P35/00; C07K14/495; C07K14/71; C07K19/00
Foreign References:
| CN112175087A | 2021-01-05 | |||
| CN111867612A | 2020-10-30 | |||
| CN110050000A | 2019-07-23 | |||
| US20180291114A1 | 2018-10-11 |
Other References:
HANNE LIND, SOFIA R GAMEIRO, CAROLINE JOCHEMS, RENEE N. DONAHUE, JULIUS STRAUSS, JAMES L GULLEY, CLAUDIA PALENA, JEFFREY SCHLOM: "Dual targeting of TGF-β and PD-L1 via a bifunctional anti-PD-L1/TGF-βRII agent: status of preclinical and clinical advances", JOURNAL FOR IMMUNOTHERAPY OF CANCER, vol. 8, no. 1, 19 December 2019 (2019-12-19), pages 1 - 10, XP055686662, DOI: 10.1136/jitc-2019-000433
Attorney, Agent or Firm:
WINGUAN PATENT AND TRADEMARK ATTORNEYS (CN)
Download PDF: